Literature DB >> 10734221

A Schistosoma protein, Sh-TOR, is a novel inhibitor of complement which binds human C2.

J M Inal1, R B Sim.   

Abstract

Human complement regulatory (also called inhibitory) proteins control misdirected attack of complement against autologous cells. Trypanosome and schistosome parasites which survive in the host vascular system also possess regulators of human complement. We have shown Sh-TOR, a protein with three predicted transmembrane domains, located on the Schistosoma parasite surface, to be a novel complement regulatory receptor. The N-terminal extracellular domain, Sh-TOR-ed1, binds the complement protein C2 from human serum and specifically interacts with the C2a fragment. As a result Sh-TOR-ed1 pre-incubated with C2 inhibits classical pathway (CP)-mediated haemolysis of sheep erythrocytes in a dose-dependent manner. In CP-mediated complement activation, C2 normally binds to C4b to form the CP C3 convertase and Sh-TOR-ed1 has short regions of sequence identity with a segment of human C4b. We propose the more appropriate name for TOR of CRIT (complement C2 receptor inhibitory trispanning).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10734221     DOI: 10.1016/s0014-5793(00)01304-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  15 in total

Review 1.  Complement evasion by human pathogens.

Authors:  John D Lambris; Daniel Ricklin; Brian V Geisbrecht
Journal:  Nat Rev Microbiol       Date:  2008-02       Impact factor: 60.633

Review 2.  Complement C2 receptor inhibitor trispanning: from man to schistosome.

Authors:  Jameel M Inal
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

3.  Inhibition of the complement membrane attack complex by Schistosoma mansoni paramyosin.

Authors:  Jiusheng Deng; Daniel Gold; Philip T LoVerde; Zvi Fishelson
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

4.  Inhibition of complement activation by recombinant Sh-CRIT-ed1 analogues.

Authors:  Kwang-Seok Oh; Mee-Hyang Kweon; Ki-Hyeong Rhee; Keyong Ho Lee; Ha-Chin Sung
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

5.  Schistosoma mansoni tetraspanning orphan receptor (SmTOR): a new vaccine candidate against schistosomiasis.

Authors:  C Lochmatter; C L Schneider; K Ingram; J Keiser; J A Schifferli
Journal:  Clin Exp Immunol       Date:  2012-12       Impact factor: 4.330

Review 6.  The complement system.

Authors:  J Vidya Sarma; Peter A Ward
Journal:  Cell Tissue Res       Date:  2010-09-14       Impact factor: 5.249

Review 7.  Eliminating Schistosomes through Vaccination: What are the Best Immune Weapons?

Authors:  Cristina Toscano Fonseca; Sergio Costa Oliveira; Clarice Carvalho Alves
Journal:  Front Immunol       Date:  2015-03-09       Impact factor: 7.561

Review 8.  Trypanosoma cruzi Evades the Complement System as an Efficient Strategy to Survive in the Mammalian Host: The Specific Roles of Host/Parasite Molecules and Trypanosoma cruzi Calreticulin.

Authors:  Galia Ramírez-Toloza; Arturo Ferreira
Journal:  Front Microbiol       Date:  2017-09-01       Impact factor: 5.640

9.  Characterization of Schistosoma japonicum tetraspanning orphan receptor and its role in binding to complement C2 and immunoprotection against murine schistosomiasis.

Authors:  Shuai Ma; Jinli Zai; Yanhui Han; Yang Hong; Min Zhang; Xiaodan Cao; Qian Han; Ke Lu; Zhixin Zhao; Jiaojiao Lin; Zhiqiang Fu
Journal:  Parasit Vectors       Date:  2017-06-09       Impact factor: 3.876

Review 10.  The emerging role of complement lectin pathway in trypanosomatids: molecular bases in activation, genetic deficiencies, susceptibility to infection, and complement system-based therapeutics.

Authors:  Ingrid Evans-Osses; Iara de Messias-Reason; Marcel I Ramirez
Journal:  ScientificWorldJournal       Date:  2013-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.